Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results , with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share was 38% above analysts’ ...

Incyte Corporation INCY reported fourth-quarter 2024 adjusted earnings of $1.43 per share, which missed the Zacks Consensus Estimate of $1.53. The company had recorded earnings of $1.06 per share in ...

Incyte (INCY) reported $1.18 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 16.3%. EPS of $1.43 for the same period compares to $1.06 a year ago. The ...

Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below ...

Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation ...

Incyte (INCY) reported $1.22 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 16.5%. EPS of $1.57 for the same period compares to -$1.82 a year ago. The ...